Immunocore reports fourth quarter and full year 2023

Immunocore reports fourth quarter and full year 2023 financial results and provides a business update KIMMTRAK (tebentafusp) net revenues of $67.6...

Related Keywords

United States ,United Kingdom ,Israel ,Rockville ,Western Australia ,Australia ,Oxfordshire ,Canada ,Ukraine ,Immunocore Imm ,Ralph Torbay ,Clayton Robertson ,Bahija Jallal ,Bristol Meyers Squibb ,Bristol Myers Squibb ,European Organisation For Research ,European Society For Medical Oncology ,Immunocore Holdings ,European Union ,Twitter ,Head Of Communications ,See The Company Annual Report On Form ,Exchange Commission ,Exchange Commission On ,Nasdaq ,Senior Notes ,Fourth Quarter ,Convertible Notes ,European Organisation ,Medical Oncology ,Response Evaluation Criteria ,Solid Tumors ,Life Extended ,Pro Forma ,Annual Report ,Call Details ,Against Cancer ,Against Virus ,Against Autoimmune ,Release Syndrome ,Product Characteristics ,Private Securities Litigation Reform Act ,Bristol Myers ,Consolidated Statement ,Years Ended December ,